Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
Executive Summary
Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.
You may also be interested in...
Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter
Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.
Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter
Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.
Novartis Starlix Takes Aim At Diabetes Prevention With 8,000-Patient Study
Novartis will seek a diabetes prevention claim for its type 2 diabetes therapy Starlix with data generated by an 8,000-patient outcomes study.